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Peripheral tolerance is an important mechanism by which the immune system can 
guarantee a second line of defense against autoreactive T and B cells. One autoimmune 
disease that is related to a break of peripheral tolerance is diabetes mellitus type 1. 
Using the RIP-GP mouse model, we analyzed the role of the spleen and lymph nodes 
(LNs) in priming CD8+ T cells and breaking peripheral tolerance. We found that diabetes 
developed in splenectomized mice infected with the lymphocytic choriomeningitis 
virus (LCMV), a finding showing that the spleen was not necessary in generating 
autoimmunity. By contrast, the absence of LNs prevented the priming of LCMV-specific 
CD8+ T cells, and diabetes did not develop in these mice. Additionally, we found 
that dendritic cells are responsible for the distribution of virus in secondary lymphoid 
organs, when LCMV was administered intravenously. Preventing this distribution with 
the sphingosine-1-phosphate receptor antagonist FTY720 inhibits the transport of 
antigen to peripheral LNs and consequently prevented the onset of diabetes. However, 
in case of subcutaneous infection, administration of FTY720 could not inhibit the onset 
of diabetes because the viral antigen is already presented in the peripheral LNs. These 
findings demonstrate the importance of preventing the presence of antigen in LNs for 
maintaining tolerance.
Keywords: autoimmune diabetes, lymph nodes, lcMV, enforced viral replication, sphingosine-1-phosphate 
receptor
inTrODUcTiOn
The immune system is divided structurally into primary lymphoid organs (PLOs) and secondary 
lymphoid organs (SLOs). PLOs include the thymus and bone marrow, which are responsible for 
the generation and differentiation of B and T cells; SLOs include the spleen and lymph nodes (LNs) 
in addition to the organized lymphoid tissues associated with mucosal membranes, such as the 
tonsils and Peyer’s patches. SLOs provide an optimal setting for effective antigen presentation and 
initiation of immune responses (1), whereas PLOs guarantee central tolerance that leads to deletion 
of autoreactive T and B cells (2). The SLOs provide a second line of defense and guarantee peripheral 
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tolerance that suppresses the autoreactive T cells that escape from 
central tolerance in the thymus (2). Any factors disturbing this 
mechanism can establish autoimmune diseases such as type 1 
diabetes (3).
The results of several experimental studies have shown that 
the encounter between antigen and naive T cells does not occur 
outside of organized lymphoid tissues (4–6) probably because 
T cells do not migrate to non-lymphoid tissues without infection 
due to the absence of homing receptors (7). The structure of the 
spleen provides optimal conditions for inducing the innate and 
adaptive immune response. In particular, the spleen captures 
antigen and guarantees sufficient viral replication to activate the 
adaptive immune system (8, 9). Interestingly, absence of spleen 
has only a slight impact on the antiviral immune response which 
can be compensated by other lymphoid organs (10), although 
splenectomy in the childhood has a big hazard of overwhelming 
infection and high susceptibility to bacterial infection (11).
Although LNs share with spleen its function as lymphoid 
organs and the ability to prime CD8+ T cells (12), but they 
differ structurally, as they possess a specialized vascular and 
lymphatic systems including high endothelial venules (HEVs), 
which considered the main sites of lymphocyte entry from the 
blood (13). Deletion of LNs leads to a dramatic defect in immune 
system (14). Additionally, skin graft transplantation experiments 
showed that applying antigen can only activate the immune 
system when afferent lymphatic vessels and draining LNs were 
intact (15). Moreover, a previous study from Gagnerault et  al. 
showed that pancreatic LNs are precisely required for priming 
of β-cell autoreactive T cells (16). These results raise the ques-
tion whether presentation of autoantigen in peripheral LNs 
is sufficient to break peripheral tolerance and for the onset of 
autoimmune diseases.
In this study using the lymphocytic choriomeningitis virus 
(LCMV), we found that early viral distribution in peripheral 
LNs is very important for guaranteeing efficient priming of CD8+ 
T cells.
research Design anD MeThODs
Mice
All experiments were performed with animals housed in single 
ventilated cages, under the authorization of the Veterinäramt 
Nordrhein Westfalen (Düsseldorf, Germany) and in accordance 
with the German law for animal protection. All mice were sex 
matched, and they were used 8–10 weeks old. RIP-GP mice (17), 
which express the LCMV glycoprotein as a transgene under the 
rat insulin promoter, were used for the analysis of autoimmune 
diabetes. P14/CD45.1 mice expressing a T cell receptor specific 
for LCMV glycoproteins 33–41 (LCMVeGP33–41) as a transgene 
were used for adoptive transfer experiments (18). Aly/aly mice 
(19) and aly/aly × RIP-GP mice were used to study the role of LNs 
in priming CD8+ T cells. CD11c-diphtheria toxin receptor (DTR) 
mice (20) and CD169-DTR mice (21) were used to investigate the 
role of dendritic cells (DCs) (CD11c+) or metallophilic marginal 
zone macrophages (CD169+) in viral transport. All mice were 
maintained on a C57BL/6 background.
Diphtheria Toxin Treatment
Dendritic cells of CD11c-DTR mice were depleted as described 
previously (22). Briefly, diphtheria toxin was injected intraperito-
neally (i.p.) at a dose of 15 µg/kg body weight (bw) daily starting 
from day 0. CD169+ macrophages of CD169-DTR mice were 
injected intraperitoneally (i.p.) at a dose 30 µg/kg bw on days −3, 
0, 1, and 2 because the recovery of CD169+ cells needs longer than 
cells in CD11c-DTR mice as it was previously described (21, 23).
Bone Marrow chimeras
To generate bone marrow chimeras, we irradiated aly/
aly × RIP-GP and RIP-GP mice with 9.5 Gy (320 kV X-rays, 3 Gy/
min, 0.35 mm copper + 1.5 mm aluminum filter; Pantak-Seifert, 
Ahrensburg, Germany). On the next day, we transferred 107 bone 
marrow cells from wild-type (WT) mice into the irradiated mice. 
After 15  days, we administered clodronate liposomes (24) to 
ensure macrophage exchange in WT > RIP-GP and WT > aly/
aly ×  RIP-GP chimeras. LCMV infection was performed after 
30 days.
splenectomy
Mice were anesthetized with ketamine (4  mg/mouse; CEVA, 
Düsseldorf, Germany) and xylazine (0.23  mg/mouse; CEVA). 
A midline laparotomy incision was made, and the spleen was 
removed after ligation of the blood vessels. Sham mice were used 
as controls.
Virus and Plaque assay
Lymphocytic choriomeningitis virus WE, originally obtained 
from F. Lehmann-Grube (Heinrich Pette Institute, Hamburg, 
Germany) was propagated in L929 cells. Mice were infected i.v. 
with LCMV at the indicated doses. Viral titers were measured 
in a plaque-forming assay using MC57 cells, as previously 
described (25).
FTY720 Treatment
Mice were treated daily by gavage at a dose of 1 mg/kg bw FTY720 
(Sigma-Aldrich, Steinheim, Germany) starting on day −2 or 3.
Flow cytometry
Tetramers were provided by the National Institutes of Health 
(NIH, Bethesda, MD, USA) Tetramer Facility. Spleen, inguinal 
lymph nodes (iLNs), or blood were stained with allophycocyanin-
labeled GP33 major histocompatibility complex class I tetramers 
(GP33/H-2Db) for 15 min at 37°C. After incubation, the samples 
were stained with anti-CD8 (eBiosciences, Franklin Lakes, NJ, 
USA) for 30 min at 4°C. Erythrocytes were then lysed with 1 ml 
BD lysing solution (BD Biosciences, Franklin Lakes, NJ, USA). 
Absolute numbers of GP33-specific CD8+ T cells per microliter 
of blood were calculated by fluorescence-activated cell sorting 
(FACS) using fluorescing beads (BD Biosciences). For intracellu-
lar staining of LCMV-NP in DCs, spleen was digested with DNase 
I (0.2 mg/ml, Sigma-Aldrich, Steinheim, Germany) and Liberase 
Collagenase 1 and 2 (0.05 mg/ml, Roche, Penzberg, Germany). 
Cells were permealized with Saponin (0.01%, Sigma-Aldrich) 
and stained with house-made LCMV-NP (VL4) antibody.
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Total rna extraction, cDna synthesis, 
and Quantitative real-time Polymerase 
chain reaction
RNA was isolated from liver, spleen, kidney, lung, and iLNs with 
the RNA Mini Kit (Qiagen, Hilden, Germany). Quantitation of 
RNA was performed with a NanoDrop ND-1000 spectropho-
tometer (Thermo Scientific, Wilmington, DE, USA). The RNA 
was reverse transcribed to cDNA with the Quantitect Reverse 
Transcription kit (Qiagen). Gene expression analysis was per-
formed with assays from Eurofins [LCMV nucleoprotein (NP), 
and LCMV glycoprotein (GP)].
Blood glucose Measurement
Serum glucose concentrations were measured with a contour 
meter (Bayer, Leverkusen, Germany). Mice were consid-
ered diabetic if the glucose concentration was higher than 
200 mg/dl.
lymphocyte Transfer
We labeled 107 splenocytes from P14 mice expressing CD45.1 
with 1  µM carboxyfluorescein succinimidyl ester (CFSE; 
Invitrogen, Carlsbad, CA, USA) and injected them intravenously 
into aly/aly or C57BL/6 control mice. The proliferation of P14 T 
cells was assessed in blood and spleen by CFSE dilution and flow 
cytometry.
histology
Immunofluorescence and conventional histology studies were 
performed as previously described (26). For immunofluores-
cence histology of the pancreas, snap-frozen tissue was stained 
with primary antibody anti-insulin (Dako, Hamburg, Germany) 
and then with secondary antibody anti-guinea pig (Jackson 
ImmunoResearch, West Grove, PA, USA) for the detection of 
insulin-producing β-islet cells and with anti-CD8 (eBioscience) 
for staining of cytotoxic CD8+ T cells. For the immunofluo-
rescence histology of the spleen, snap-frozen tissue was either 
stained with LCMV nucleoprotein (VL-4, green, made in-house) 
and/or for metallophilic marginal zone macrophages (CD169+, 
red, eBioscience)/DCs (CD11c+, red, eBioscience) and B cells 
(B220, blue, eBioscience)/T cells (CD90.2, blue, eBioscience). 
For conventional immunohistochemistry, snap-frozen tissue 
was stained with rat anti-mouse polyclonal antibody to LCMV 
nucleoprotein (VL4, made in-house). Polyclonal anti-rat biotin 
antibody (eBioscience) and anti-biotin streptavidin–peroxidase 
(Thermo Fisher Scientific) were then used before visualization 
with a 2-solution 3,3′-diaminobenzidine (DAB) staining kit 
(Invitrogen).
statistical analysis
If not otherwise stated, data are expressed as means plus or minus 
SEM. Student’s t-test was used to detect statistically significant 
differences between groups, and the log-rank (Mantel–Cox) 
test was used to detect statistically significant differences in the 
incidence of diabetes. Significant differences between several 
groups were detected by two-way analysis of variance. Statistical 
significance was set at the level of P < 0.05.
resUlTs
route of lcMV infection influences the 
Viral Titer Kinetic and cD8+ T cell number 
in Blood
First, we determined viral replication in the spleen and periph-
eral iLNs after administration of virus by various routes of 
infection. Intravenous (i.v.) infection of C57BL/6 mice with 
LCMV strain WE [lymphocytic choriomeningitis virus strain 
WE (LCMV-WE); 200 plaque-forming units (PFUs)] led to 
high levels of viral replication in the spleen and LNs 3  days 
after infection (Figures 1A,B). As expected, a dose of LCMV 
≤200 PFU does not lead to viral replication in the liver (9, 27). 
In contrast, subcutaneous (s.c.) infection of C57BL/6 mice with 
the same dose of LCMV caused higher viral replication in LNs 
at day 3 but delayed viral titers in the spleen (Figures 1C,D). 
In line with these results, we found that LCMV-specific CD8+  
T cell number in blood was higher after i.v. infection compared 
to s.c. infection (Figure 1E). We conclude that viral titer kinet-
ics and CD8+ T cell number in the blood are influenced by the 
route of infection.
Dcs are the cardinal contributors to the 
Transport of antigen to lns
Next, we investigated which cells are responsible for the transfer 
of viral antigen to or between LNs. Immunofluorescent staining 
of spleen sections showed that most of the virus was co-localized 
with CD169+ macrophages (Figure 2A) and with CD11c+ cells 
(Figure 2B). FACS analysis showed also that most of the LCMV 
was found in CD11c+ cells (Figure 2C). To determine whether 
CD169+ macrophages, CD11c+ DCs, or both are responsible for 
viral transfer, we used CD169-DTR mice or CD11c-DTR mice. 
Treating these mice with diphtheria toxin depletes CD169+ cells or 
DCs, respectively (Figures S1 and S2 in Supplementary Material). 
CD169+ cells exerted no influence on antigen transfer because 
viral titer was higher in CD169-DTR mice than in WT mice in 
the spleen and not significantly different in iLNs (Figure  2D). 
By contrast, CD11c-DTR mice exhibited lower viral titers in the 
spleen in comparison to WT mice, whereas no viral antigen could 
be detected in LNs when DCs were absent (Figure  2E). From 
these data, we conclude that DCs contribute to the transfer of 
virus to LNs.
The spleen is not necessary in 
generating autoimmunity
Previous results raised the question whether LNs alone, without 
assistance from the spleen, could prime CD8+ T cells. To answer 
this question, we first investigated the impact of the spleen on viral 
uptake by LNs or on viral replication in LNs. Viral uptake in WT 
splenectomized (splx) and control mice (sham) was measured. 
Viral copy numbers (Figure 3A) and viral titers (Figure 3B) were 
similar in both groups, a finding indicating that viral replication 
in LNs does not depend on the spleen.
To investigate the activation of autoreactive CD8+ T cells and 
the onset of diabetes, we infected transgenic splenectomized 
and sham mice expressing the LCMV glycoprotein under 
FigUre 1 | route of lymphocytic choriomeningitis virus (lcMV) infection influences the viral titer kinetic and cD8+ T number in blood. (a,B) 
C57BL/6 mice were infected intravenously (i.v.) with 200 plaque-forming units (PFUs) lymphocytic choriomeningitis virus strain WE (LCMV-WE). (a) Conventional 
immunohistochemistry of LCMV in the spleen and inguinal lymph nodes (iLNs) on day 3 (d3) and day 6 (d6) after infection (n = 3). Scale bars on main images 
represent 500 µm, and scale bars on inlays represent 100 µm. Histological images were captured at 4× magnification (main images) or 20× magnification 
(inlays) with a Keyence BZ-9000E microscope. One of the three representative images is shown. (B) Viral titers in the spleen, iLNs, and liver were measured at 
the indicated time points (n = 7, pooled from two experiments). Black squares = spleen; white squares = iLNs; green squares = liver. (c,D) C57BL/6 mice were 
infected subcutaneously (s.c.) with 200 PFU LCMV-WE. (c) Conventional histological staining of LCMV in the spleen and iLNs at the indicated time points (d3 
and d6). Scale bars on main images represent 500 µm, and scale bars on inlays represent 100 µm (n = 3). Histological images were captured at 4× 
magnification (main images) or 20× magnification (inlays) with a Keyence BZ-9000E microscope. One of the three representative images is shown. (D) Viral 
titers in the spleen, iLNs, and liver were measured on d3 and d6 after subcutaneously infection (n = 7; pooled from two experiments). Black squares = spleen; 
white squares = iLNs; green squares = liver. (e) C57BL/6 mice were intravenously (i.v.) or subcutaneously (s.c.) infected with 200 PFU LCMV-WE. Tetramer (Tet) 
GP33+ CD8+ T cells in the blood were counted on d9, d12, and d15 after infection (n = 7; pooled from two experiments). Black squares = LCMV-WE i.v.; white 
squares = LCMV-WE s.c. Statistical significance was set at the level of P < 0.05 and was determined by two-way analysis of variance (B,D,e). **P < 0.01, 
***P < 0.001.
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FigUre 2 | Dendritic cells (Dcs) are the cardinal contributors of the transport of antigen to lymph nodes. (a,B) C57BL/6 mice were infected 
intravenously (i.v.) with 200 plaque-forming units (PFUs) of lymphocytic choriomeningitis virus strain WE (LCMV-WE). Immunofluorescent sections of spleen were 
stained for (a) LCMV nucleoprotein (LCMV-NP; green), CD169+ macrophages (CD169; red), and B cells (B220; blue) on day 3 after infection or for (B) LCMV-NP 
(green), DCs (CD11c; red),  and B cells (B220; blue) on day 5 (d5) after infection. Scale bars represent 100 µm (n = 3). Fluorescence images were captured at 20× 
magnification with a Keyence BZ-9000E microscope. One of the three representative images is shown. (c) C57BL/6 mice were infected i.v. with 2 × 106 PFU 
LCMV-WE. Virus-positive DCs were measured in spleen tissue on day 3 after infection by fluorescence-activated cell sorting (n = 5, from one experiment). Black 
squares = naive; white squares = LCMV. (D) CD169-diphtheria toxin receptor (DTR) and littermate control mice were treated with diphtheria toxin [30 µg/kg body 
weight (bw)] on days −3, 0, 1, and 2. On day 0, mice were infected with 200 PFU LCMV-WE. Viral titers were measured in the spleen and iLNs on d3 after infection 
(n = 6, pooled from two experiments). Black squares = wild type (WT); white squares = CD169-DTR. (e) CD11c-DTR and littermate control mice (WT) were treated 
daily with diphtheria toxin (15 µg/kg bw) from day 0 until day 2. On day 0, mice were infected with 2 × 106 PFU LCMV-WE. Viral titers were measured in the spleen 
and inguinal lymph nodes (iLNs) on d3 after infection (n = 8, pooled from two experiments). Black squares = WT; white squares = CD11c-DTR. Statistical 
significance was set at the level of P < 0.05 and was determined by Student’s t-test (c–e). n.s., not significant; **P < 0.01, ***P < 0.001.
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FigUre 3 | The spleen is not necessary in generating autoimmunity. (a) Sham and splenectomized (splx) C57BL/6 wild-type (WT) mice were infected 
intravenously with 2 × 106 plaque-forming units (PFUs) of lymphocytic choriomeningitis virus strain WE (LCMV-WE). After 1 h, lymphocytic choriomeningitis virus 
(LCMV) glycoprotein (GP) or nucleoprotein (NP) copies were counted in the liver, spleen, kidney, lung, and iLNs by quantitative real-time polymerase chain 
reaction (qRT-PCR) (n = 4, from one experiment). Black column = WT sham; white column = WT splx. (B) Sham and splenectomized C57BL/6 mice were 
intravenously infected with 20 PFU of LCMV-WE. After 6 days, viral titers were measured in the indicated organs (n = 8; pooled from two experiments). Black 
column = WT sham; white column = WT splx. mLN, mesenteric lymph node; iLNs, inguinal lymph nodes and pLNs, pancreatic lymph nodes. (c,D) Transgenic 
splenectomized and sham mice expressing the LCMV-GP under control of the rat insulin promoter (RIP-GP mice) were infected with 200 PFU LCMV-WE.  
(c) Tetramer (Tet) GP33+ CD8+ T cells in the blood were counted at the indicated time points (n = 8–9, pooled from two experiments). Black squares = RIP-GP 
sham; white squares = RIP-GP splx. (D) The onset of diabetes was monitored (n = 9–10, pooled from two experiments). Black squares = RIP-GP sham; white 
squares = RIP-GP splx. Statistical significance was set at the level of P < 0.05 and was determined by two-way analysis of variance (c) and log-rank  
(Mantel–Cox) test (D). n.s., not significant.
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control of the rat insulin promoter (RIP-GP) (as controls) 
with LCMV. Surprisingly, after infection splenectomized mice 
exhibited strong but delayed priming of autoreactive CD8+ 
T cells in comparison to control mice (Figure 3C). This finding 
indicates that removing the spleen does not prevent the onset 
of diabetes (Figure 3D). The delay in CD8+ T cell activation in 
splenectomized mice may be due to the reduction of autoreactive 
T cells in these mice. Therefore, we conclude that the spleen is 
not necessary in generating autoimmunity.
Presence of lns and Organized splenic 
structure are essential for the Onset of 
Diabetes
To study the role of LNs in the incidence of diabetes, we crossed 
mice lacking LNs [alymphoplasia/alymphoplasia (aly/aly)] with 
RIP-GP mice to get homozygous double mutants mice. Aly/
aly mice have additional defects in other immune cells, such 
as B and T cells (10, 28). To overcome some of these defects, 
we generated bone marrow chimeras and transferred bone 
FigUre 4 | Presence of lymph nodes (lns) and organized splenic structure are essential for onset of diabetes. (a–c) Transgenic mice expressing the 
lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) under control of the rat insulin promoter (RIP-GP mice) and homozygous double transgenic mice 
lacking LNs [alymphoplasia/alymphoplasia mice (aly/aly)] and crossed with RIP-GP mice (aly/aly × RIP-GP mice) were lethally irradiated. One day later, their immune 
systems were reconstituted with 107 bone marrow cells from C57BL/6 wild-type (WT) mice. Thirty days later, mice were infected with 200 plaque-forming units 
(PFUs) of LCMV. (a) Serum glucose concentrations were determined on day 6 (d6), d9, d12, and d15 after infection (n = 4, from one experiment). Black 
squares = WT > RIP-GP; white squares = WT > aly/aly × RIP-GP. (B) Tetramer (Tet) GP33-specific CD8+ T cells in the blood were counted by flow cytometry at the 
indicated time points after LCMV infection (n = 4, from one experiment). Black squares = WT > RIP-GP; white squares = WT > aly/aly × RIP-GP. (c) 
Immunofluorescence histology of pancreas sections stained for insulin (green) and CD8+ T cells (red) on d6 after infection (n = 3; scale bar, 50 µm). Fluorescence 
images were captured at 20× magnification with a Keyence BZ-9000E microscope. One of the three representative images is shown. (D) 107 splenocytes 
transferred from P14 × CD45.1 mice into WT and aly/aly mice. After 24 h, mice were infected with 200 PFU LCMV, and CD45.1+/CD8+ T cells were counted in 
blood on day 4 (d4) and day 8 (d8) and in spleen day 8 (d8) after infection (n = 3, from one experiment). Black squares or column = WT; white squares or 
column = aly/aly. Statistical significance was set at the level of P < 0.05 and was determined by two-way analysis of variance [(a,B,D) (left)] or Student’s t-test 
[(D) (right)]. *P < 0.5; ***P < 0.001.
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marrow from WT mice into aly/aly  ×  RIP-GP mice. After 
reconstitution, we infected these mice intravenously (i.v.) with 
the diabetes-inducing dose of LCMV-WE and monitored the 
onset of diabetes. Surprisingly, diabetes did not develop in these 
mice, whereas control mice exhibited elevated glucose levels 
(Figure 4A). This phenotype was associated with the absence of 
virus-specific CD8+ T cells in the mice lacking LNs (Figure 4B). 
Moreover, the infiltration of CD8+ T cells into the pancreas was 
blunted, and β-islet cells were not destroyed because the LNs 
were absent (Figure 4C).
To investigate the defect in the priming of CD8+ T cells in the 
absence of LNs, we transferred splenocytes from P14/CD45.1 
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mice into WT and aly/aly mice and infected both groups, 
with LCMV. We measured the number of transferred CD45.1+ 
CD8+ T cells and found that these T cells proliferate much 
more stronger in WT mice than in aly/aly mice (Figure  4D). 
Taking together, these results with the fact that aly/aly mice have 
architectural defect in the spleen, even with the bone marrow 
chimera strategy as shown by Karrer et al. (10), we conclude that 
peripheral LNs and organized structure of the spleen play an 
essential role in priming of peripheral CD8+ T cells and affecting 
the maintenance of tolerance.
FTY720 Prevents Viral Transfer to lns and 
Thereby inhibits the Onset of Diabetes
A previous study showed that the sphingosine-1-phosphate 
receptor antagonist (FTY720) can modulate the trafficking of 
DCs in vivo (29). To examine its influence on viral transfer, we 
infected C57BL/6 WT mice i.v. or s.c. with LCMV. Additionally, 
we treated one group of mice daily with FTY720 beginning 
on day −2 (untreated mice served as controls). Interestingly, 
FTY720 treatment inhibited the transfer of virus from spleen 
to iLNs in i.v.-infected mice or from ipsilateral iLN to spleen or 
contralateral iLNs in s.c.-infected mice (Figure 5A). The inhibi-
tion of antigen transfer was not due to a reduction in the number 
of DCs because FTY720 treatment has no effect on DC number 
without infection (Figure 5B). The prevention of viral transfer 
from LNs to the spleen after s.c. infection was associated with 
the absence of priming of total and virus-specific CD8+ T cells in 
the spleen and in the contralateral iLN but not in the ipsilateral 
iLN (Figures 5C,D).
We and other groups have shown that FTY720 treatment 
can prevent the onset of diabetes in RIP-GP mice infected i.v. 
with LCMV (Figure 5E) (30). We speculated that viral replica-
tion in LNs of RIP-GP mice after s.c. infection is sufficient to 
prime CD8+ T cells even during FTY720 treatment. Indeed, we 
found that the administration of FTY720 did not inhibit the 
onset of diabetes in s.c.-infected mice (Figure  5F). To prove 
that the prevention of onset of diabetes in i.v.-infected mice 
was due to the inhibition of antigen spreading to lymphoid 
organs and not due to a direct effect on T-lymphocytes circula-
tion, we infected three groups of C57BL/6 mice intravenously 
with LCMV. Two groups were treated additionally with 
FTY720 starting from day −2 or from day 3 after infection. 
Administration of FTY720 before infection prevented viral 
spread and consequently led to less LCMV-specific CD8+  
T cell number in the iLNs in comparison to the untreated 
group, whereas the group that received FTY720 starting from 
day 3 after infection and have already viral distribution in iLNs 
showed similar number of LCMV-specific CD8+ T cells to the 
untreated one (Figure 5G). To check whether late treatment of 
FTY720 is enough to onset autoimmune response, we treated 
RIP-GP mice with FTY720 starting either from day −2 or 
from day 3 after infection. We found that treating mice with 
FTY720 at later time point did not prevent the priming of auto-
reactive CD8+ T cells and the onset of diabetes (Figure 5H). 
Additionally, treating mice with FTY720 only between days −2 
and 3 was enough to reduce virus-specific CD8+ T cell priming 
in the inguinal LNs (Figure 5I), which suggest that the effect 
of FTY720 is not direct on CD8+ T cells but on DCs. From 
these findings, we conclude that viral transfer is dependent on 
sphingosine-1-phosphate and that antigen replication in LNs 
is essential for priming peripheral CD8+ T cells and breaking 
immunological tolerance.
DiscUssiOn
The results of this study suggest that presentation of autoan-
tigen in peripheral LNs is sufficient for priming autoreactive 
CD8+ T  cells and generating autoimmune disease. Here, 
we could show that the dendritic cell-dependent transport 
of autoantigen in LNs plays an important role in breaking 
peripheral tolerance. Administration of FTY720 prevents 
antigen spreading between lymphoid organs, which is essential 
for priming of autoreactive CD8+ T cells in peripheral LNs. 
It is still to be addressed whether the phenotype observed by 
Pinschewer et al. (30) showing a reduction of memory CD8+ 
T cells recruitment after FTY720 treatment was also due to 
the inhibition of antigen distribution or to lymphocyte arrest 
in lymphoid organs.
Although our study confirmed the finding which made 
by Karrer et  al. showing the importance of LNs in activation 
the adaptive immune system (14), the current study does not 
exclude either the important role of the spleen in the immune 
system or the fact that most children born without a spleen die of 
infection during the first months after birth (31, 32). Moreover, 
the architectural defect in the spleen of aly/aly mice, even with 
the bone marrow chimera strategy as shown by Karrer et al. 
(10), make it difficult to assert that spleen alone is not enough to 
prime autoreactive T cells.
Oral administration of FTY 720 induces immune tolerance 
in mice through induction of regulatory T cells, inhibition of 
effector T cell responses, and DC trafficking (29). In this study, 
we found that the effect of FTY720 as immune tolerance inducer 
is depending on the route of infection. After i.v. infection with 
LCMV, FTY720 prevents the transfer of autoantigen to peripheral 
LNs and consequently inhibits the priming of autoreactive CD8+ 
T cells, whereas after s.c. infection, FTY720 exerts no prevention 
on onset of diabetes. Additional investigations are necessary for 
determining whether APC trafficking is completely inhibited 
or whether only the migration of autoantigen-carrying cells is 
influenced.
Interestingly, the onset of diabetes in non-obese diabetic 
mice was inhibited by continuous treatment with FTY720 (33). 
Withdrawal of treatment led to more rapid development of dis-
ease independent of the pancreatic lymph nodes. Our results may 
explain this phenotype, in which the prevention of autoantigen 
transport in LNs by the administration of FTY720 can inhibit the 
development of diabetes.
It is still to be investigated why LNs provide a better 
environment than the spleen. One explanation could be the 
location of LNs where they afford a better distribution of T 
cells. Another explanation may be due to viral load in the 
lymphoid organs, where we see that LNs have higher antigen 
amount than spleen if it is compared with size of the organ and 
consequently leads to better antigen–T cell affinity. The reason 
FigUre 5 | continued
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FigUre 5 | FTY720 prevents viral transfer to lymph nodes and thereby inhibits the onset of diabetes. (a) C57BL/6 wild-type (WT) mice were 
treated daily with a sphingosine-1-phosphate antagonist [FTY720; 1 mg/kg body weight (bw)] starting from day −2 or were left untreated. Mice were 
infected intravenously (i.v.) or subcutaneously (s.c.) with 20 plaque-forming units (PFUs) of lymphocytic choriomeningitis virus strain WE (LCMV-WE). Viral 
titer was measured in the spleen, inguinal lymph nodes (iLNs) and liver on day 3 (d3; i.v.) or day 6 (d6; s.c.) after infection (n = 6; pooled from two 
experiments). Black column = LCMV; white column = LCMV + FTY720. (B) C57BL/6 WT mice were treated daily with FTY720 (1 mg/kg bw) starting from 
day −2 or were left untreated. CD11c+ cells in the spleen, iLNs, and blood were counted on day 0 (n = 6, pooled from two experiments). Black 
column = WT untreated; white column = WT + FTY720. (c,D) C57BL/6 WT mice were treated daily with FTY720 (1 mg/kg bw) starting on day −2 or were 
left untreated. Mice were infected s.c. with 20 PFU LCMV-WE. On day 12, total and LCMV-specific CD8+ T cells were counted in the spleen (c) and iLNs 
(D) (n = 6, pooled from two experiments). Black column = LCMV; white column = LCMV + FTY720. (e,F) Transgenic mice expressing the lymphocytic 
choriomeningitis virus (LCMV) glycoprotein (GP) under control of the rat insulin promoter (RIP-GP) were treated daily with FTY720 (1 mg/kg bw) starting 
from day −2 or were left untreated. Mice were intravenously or subcutaneously infected with 20 PFU LCMV-WE. Onset of diabetes was measured (e) i.v., 
n = 6–8, pooled from two experiments; (F) s.c., n = 5–6, pooled from two experiments. Black squares = RIP-GP LCMV; white squares = RIP-GP 
LCMV + FTY720. (g) C57BL/6 WT mice were treated daily with a sphingosine-1-phosphate antagonist [FTY720; 1 mg/kg body weight (bw)] starting from 
day −2 or 3 of infection or left untreated. Mice were infected intravenously (i.v.) with 20 PFU of LCMV-WE. On day 12, tetramer (Tet) GP33-specific CD8+  
T cells in iLNs were counted by flow cytometry (n = 8, pooled from two experiments). Black column = LCMV; white column = LCMV + FTY720 (starting 
day −2); red column = LCMV + FTY720 (starting d3). (h) Transgenic mice expressing the LCMV glycoprotein (GP) under control of the rat insulin promoter 
(RIP-GP) were treated daily with FTY720 (1 mg/kg bw) starting from day −2 or 3 of infection or were left untreated. Mice were intravenously infected with 
20 PFU LCMV-WE. Onset of diabetes was measured (n = 6, pooled from two experiments). Black squares = RIP-GP LCMV; white squares = RIP-GP 
LCMV + FTY720 day −2; red squares = RIP-GP LCMV + FTY d3. (i) C57BL/6 WT mice were treated daily with a sphingosine-1-phosphate antagonist 
[FTY720; 1 mg/kg body weight (bw)] starting from day −2 till day 3, from day 3 till day 8, or day 2 till day 8 of infection or left untreated. Mice were infected 
intravenously (i.v.) with 20 PFU of LCMV-WE. On day 9, tetramer (Tet) GP33-specific CD8+ T cells in iLNs were counted by flow cytometry (n = 6, pooled 
from two experiments). Black column = LCMV; gray column = LCMV + FTY720 (starting day −2 till day 3); red column = LCMV + FTY720 (starting day 3 
till day 8); white column = LCMV + FTY720 (starting day −2 till day 8). Statistical significance was set at the level of P < 0.05 and was determined by 
Student’s t-test (a–D,g,i) or log-rank (Mantel–Cox) test (e,F,h). n.s., not significant; *P < 0.5; **P < 0.01; ***P < 0.001.
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behind that may be the absence of red pulp macrophages 
in LNs but not in spleen which are strong IFN-I-dependent 
antiviral APCs (8). Or third, the presence of HEVs in LNs, 
but not in spleen (34), can provide an optimal lymphocyte 
trafficking.
Finally, our findings give an explanation why subcutaneously 
vaccination may be more efficient than intravenously antigen 
administration. The subcutaneous route of administration 
provide sufficient priming of T cells and simultaneously help 
to avoid undesirable systemic adverse effects, such as toxicity 
or vaccine-wide distribution in various organs such as the liver, 
where no interaction occurs between antigen and the adaptive 
immune system.
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